News headlines about TherapeuticsMD (NASDAQ:TXMD) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. TherapeuticsMD earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.5646453436093 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s analysis:
- TherapeuticsMD, Inc. (TXMD) stands -8.87% away from 50 SMA: Technical Watch – Nasdaq Chronicle (nasdaqchronicle.com)
- Analysts Watch-List Stock: TherapeuticsMD, Inc. (TXMD) – Wall Street Morning (wallstreetmorning.com)
- TherapeuticsMD Inc (NASDAQ:TXMD) Reports FDA Acceptance Of New Drug Application And PDUFA Date for TX … – The Herald of Finance (heraldfinance.com)
- TherapeuticsMD, Inc., (NASDAQ: TXMD) – Stock to Watch – Stock Watch (stocksnewstimes.com)
- One Most Risky Stock to Own In 2018: TherapeuticsMD, Inc. (TXMD) – Wallstreet Investorplace (wallstreetinvestorplace.com)
A number of research analysts recently weighed in on TXMD shares. Cantor Fitzgerald restated a “buy” rating and set a $31.00 target price on shares of TherapeuticsMD in a research note on Wednesday, November 29th. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research note on Thursday, November 30th. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research note on Tuesday, December 12th. Deutsche Bank set a $9.00 price target on shares of TherapeuticsMD and gave the stock a “buy” rating in a research note on Wednesday, December 20th. Finally, Oppenheimer set a $10.00 price target on shares of TherapeuticsMD and gave the stock a “buy” rating in a research note on Wednesday, December 20th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $14.50.
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at $5.25 on Friday. The company has a market cap of $1,133.94, a price-to-earnings ratio of -13.82 and a beta of 1.36. TherapeuticsMD has a one year low of $3.50 and a one year high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Tuesday, February 20th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The company had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $4.66 million. TherapeuticsMD had a negative return on equity of 63.67% and a negative net margin of 458.49%. The firm’s revenue for the quarter was down 8.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.12) EPS. analysts expect that TherapeuticsMD will post -0.38 earnings per share for the current year.
WARNING: “TherapeuticsMD (TXMD) Earns News Sentiment Score of 0.10” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2018/03/17/therapeuticsmd-txmd-earns-news-sentiment-score-of-0-10.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.